Tempest Therapeutics’ (TPST) “Buy” Rating Reaffirmed at HC Wainwright

Tempest Therapeutics (NASDAQ:TPSTGet Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $47.00 target price on the stock.

Tempest Therapeutics Price Performance

TPST opened at $1.08 on Wednesday. The stock’s 50 day moving average price is $1.21 and its 200-day moving average price is $1.98. Tempest Therapeutics has a 52-week low of $0.86 and a 52-week high of $6.00. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.17 and a current ratio of 2.17. The stock has a market capitalization of $27.23 million, a PE ratio of -0.67 and a beta of -1.78.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC grew its stake in shares of Tempest Therapeutics by 69.2% during the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after purchasing an additional 11,689 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Tempest Therapeutics during the 2nd quarter valued at approximately $55,000. Empower Advisory Group LLC bought a new stake in Tempest Therapeutics in the 3rd quarter valued at $49,000. Finally, Fullcircle Wealth LLC bought a new stake in shares of Tempest Therapeutics in the third quarter worth about $87,000. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

(Get Free Report)

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.

Featured Articles

Analyst Recommendations for Tempest Therapeutics (NASDAQ:TPST)

Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.